1. Home
  2. MGNX vs MAPS Comparison

MGNX vs MAPS Comparison

Compare MGNX & MAPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.43

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Logo WM Technology Inc.

MAPS

WM Technology Inc.

HOLD

Current Price

$0.91

Market Cap

106.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGNX
MAPS
Founded
2000
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
94.9M
106.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
MGNX
MAPS
Price
$1.43
$0.91
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$3.20
$2.61
AVG Volume (30 Days)
907.4K
825.5K
Earning Date
11-12-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.07
Revenue
$127,626,000.00
$179,305,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.43
P/E Ratio
N/A
$12.62
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$0.72
52 Week High
$3.68
$1.65

Technical Indicators

Market Signals
Indicator
MGNX
MAPS
Relative Strength Index (RSI) 40.27 48.32
Support Level $1.33 $0.84
Resistance Level $1.55 $0.90
Average True Range (ATR) 0.10 0.05
MACD 0.00 0.01
Stochastic Oscillator 9.82 89.55

Price Performance

Historical Comparison
MGNX
MAPS

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About MAPS WM Technology Inc.

WM Technology Inc is a technology and software infrastructure provider to the cannabis industry. It comprises the B2C platform Weedmaps, and B2B software WM Business. Its revenues are derived primarily from monthly subscriptions to Weedmaps for Business, featured and deal listings and other WM Ad solutions. The Weedmaps for Business subscriptions generally have one-month terms that automatically renew unless notice of cancellation is provided in advance. Featured and deal listings and other WM Ad solutions are offered as add-on products to the Weedmaps for Business subscriptions. Featured and deal listings provide customers with premium placement ad solutions and discount and promotion pricing tools. Other WM Ad solutions include banner ads and promotion tiles on marketplace ads.

Share on Social Networks: